Stock analysis, trade plans, and proprietary indicators by Trend Edge.
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Exchange: NASDAQ
IPO Date: May 24, 2018
Headquarters: 105 Piccadilly, London, United Kingdom, W1J 7NJ
Founder-Led: Yes — Sanj K. Patel (CEO & Chairman of the Board), Eben P. Tessari (Chief Strategy Officer), Aaron Isadore Young (Chief Intellectual Property Officer)
Key Metrics
Current Price
$51.84
Market Cap
$4.18B
Float
40.3M
Shares Outstanding
46.3M
P/E (Forward)
48.54
P/E (TTM)
59.65
Price/Sales (TTM)
5.54
vs. Analyst Target
+22.5% to analyst PT
Profit Margin
9.69%
Operating Margin (TTM)
13.66%
Revenue (TTM)
$754M
Earnings Growth (YoY)
145.50%
Dividend Rate
None
Analyst Target Price
$63.50 (6 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$7.7M
-$161M
-$3.8M
-$155M
2021
$38.5M
-$158M
$29.4M
-$154M
2022
$220M
$183M
$197M
$12.2M
2023
$270M
$14.1M
$214M
-$22.9M
2024
$423M
-$43.2M
$362M
-$43.9M
2025
$678M
$59.0M
$370M
$90.4M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
$157M
$17.8M
Sep 2025
$181M
$18.4M
Dec 2025
$202M
$14.2M
Mar 2026
$214M
$22.6M
Ownership & Float
Insider Ownership
3.6%
Institutional Ownership
101.8%
Short Float
8.8%
% of All Funds Holding
2.49%
Number of Funds Holding
205
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$50.48
Near-term / short-term trend
Weekly
40-Week SMA
$43.35
Medium-term trend
Weekly
80-Week SMA
$33.77
Cyclical trend (business cycle)
Weekly
200-Week SMA
$23.82
Secular trend (multi-year)
Monthly
10-Month SMA
$43.53
Near-term monthly trend
Monthly
20-Month SMA
$33.70
Medium-term monthly trend
Monthly
40-Month SMA
$25.80
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$49.00
support
1.50x
0 months ago
$45.00
support
1.18x
1 months ago
$27.60
support
1.20x
9 months ago
$22.10
support
1.51x
12 months ago
$18.50
support
1.55x
21 months ago
Historical Earnings Reactions (32 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.64%
0.35%
62.50%
9.19%
-2.64%
1 Day
1.01%
-0.32%
50.00%
19.01%
-6.28%
1 Week
2.57%
0.90%
56.25%
17.74%
-23.24%
2 Weeks
0.79%
0.63%
53.13%
23.83%
-20.28%
1 Month
7.21%
4.15%
61.29%
94.38%
-19.39%
Next earnings: July 17, 2026 (50 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
0.6%
50.0%
8
Feb
4.7%
75.0%
8
Mar
-4.2%
37.5%
8
Apr
2.8%
37.5%
8
May
0.5%
71.4%
7
Jun
5.2%
75.0%
8
Jul
5.3%
62.5%
8
Aug
3.2%
50.0%
8
Sep
1.1%
50.0%
8
Oct
-10.8%
12.5%
8
Nov
19.3%
87.5%
8
Dec
2.9%
50.0%
8
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.07%
52.5%
377
Tuesday
0.52%
51.3%
415
Wednesday
0.04%
49.0%
410
Thursday
-0.23%
45.2%
403
Friday
0.22%
52.2%
404
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 101.8%
Insider Transactions — Smart Summary
Total insider ownership: 3.6%
Founder-led management: Sanj K. Patel (CEO & Chairman of the Board), Eben P. Tessari (Chief Strategy Officer), Aaron Isadore Young (Chief Intellectual Property Officer)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Kiniksa Pharmaceuticals Ltd
(KNSA) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.